Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
Conditions
Glomerulonephritis, IGA · Immunoglobulin A Nephropathy
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
Contact: Principal Investigator (Dana Rizk)UCLA Medical Center, Los Angeles, California, United States
Contact: Principal Investigator (Mrinalini Sarkar)Central Florida Kidney Specialists, Orlando, Florida, United States
Contact: Principal Investigator (Arvind Madan)Georgia Nephrology Research Inst, Lawrenceville, Georgia, United States
Contact: Principal Investigator (James A Tumlin)CaRe Research, Chubbuck, Idaho, United States
Contact: Principal Investigator (Hira Siktel)DaVita Clinical Research, Las Vegas, Nevada, United States
Contact: Principal Investigator (Mark Vishnepolsky)University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Contact: Principal Investigator (Andrew Lazar)OSU Wexner Medical Center, Columbus, Ohio, United States
Contact: Principal Investigator (Isabelle Ayoub)Prolato Clinical Research Center, Houston, Texas, United States
Contact: Principal Investigator (Sreedhar Mandayam)Novartis Investigative Site, CABA, Buenos Aires, Argentina
Novartis Investigative Site, CABA, Buenos Aires, Argentina
Novartis Investigative Site, Córdoba, Córdoba Province, Argentina
Novartis Investigative Site, Ashdod, Israel
Novartis Investigative Site, Hadera, Israel
Novartis Investigative Site, Haifa, Israel
Novartis Investigative Site, Nahariya, Israel
Novartis Investigative Site, Kuala Lumpur, Selangor, Malaysia
Novartis Investigative Site, Riyadh, Saudi Arabia
Study leads
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals